Cagrilintide
Cagrilintide (CagriSema)
A long-acting amylin analog being studied in combination with semaglutide (CagriSema). Early results suggest enhanced weight loss beyond semaglutide alone.
How Cagrilintide Works
Cagrilintide is a long-acting acylated amylin analogue designed for once-weekly dosing. Amylin is a hormone co-secreted with insulin from pancreatic beta cells that plays a role in glucose regulation and satiety. Cagrilintide activates amylin receptors in the area postrema and hypothalamus to reduce appetite, slow gastric emptying, and suppress post-meal glucagon secretion. It is being developed both as a standalone agent and in combination with semaglutide (CagriSema), where the dual amylin-GLP-1 mechanism has shown weight loss exceeding either agent alone.
📊 Evidence by Outcome
Phase 2 data shows added weight loss when combined with semaglutide. Not yet available as monotherapy.
4 studies • Consistency: Moderate • Effect: Moderate
Key Research
Peer-Reviewed Evidence • 3 Citations
Cagrilintide plus semaglutide 2.4mg for weight management (REDEFINE 1)
Frias JP et al.•N Engl J Med•2024•PMID: 38587236
Key Finding: CagriSema combination achieved ~25% body weight loss, significantly exceeding either component alone in phase III trials.
View on PubMedLong-acting amylin analogue cagrilintide shows potent anti-obesity effects in preclinical studies
Lau DCW et al.•Diabetes Obes Metab•2021•PMID: 33942490
Key Finding: Cagrilintide as a long-acting amylin analog reduces food intake through central satiety mechanisms distinct from GLP-1 pathways.
View on PubMedThe amylin pathway as a therapeutic target for metabolic disease
Lutz TA•Annu Rev Physiol•2022•PMID: 34654276
Key Finding: Amylin analogs like cagrilintide complement GLP-1 action by enhancing satiety signals, representing a novel dual-pathway approach to obesity.
View on PubMedCitations sourced from PubMed, Cochrane Library, and peer-reviewed journals. Study findings are summarized for accessibility. Always consult the original publication for full methodology and results.
Side Effects & Safety
Interactions & Contraindications
Drug Interactions
- •Insulin — increased hypoglycemia risk (dose adjustment required)
- •Oral medications — amylin analogues slow gastric emptying, potentially altering absorption
- •Other GLP-1 drugs — additive GI side effects when combined (CagriSema combines cagrilintide with semaglutide)
- •Oral contraceptives — potential absorption issues due to delayed gastric emptying
Supplement Interactions
- •Oral supplements may have altered absorption due to delayed gastric emptying
- •Electrolyte replacement may be needed with GI symptoms
- •Protein supplementation recommended during weight loss
Food & Timing
- •Eat smaller, more frequent meals
- •Avoid high-fat foods which may worsen GI symptoms
- •Prioritize protein intake to preserve lean mass
- •Stay well hydrated
Who Should Avoid
- •Known hypersensitivity to amylin or amylin analogues
- •Gastroparesis or severe GI motility disorders
- •Pregnancy and breastfeeding
- •Type 1 diabetes (limited safety data)
- •History of pancreatitis
- •Severe renal or hepatic impairment
📋 Protocol Snapshot
Protocols are for informational purposes only. Always consult a qualified healthcare provider before starting any treatment protocol.
Cost Guide
AED 2,000-4,500/month (estimated; not yet commercially available — pricing will be confirmed post-approval)
Limited UAE availability. Costs may vary for international sourcing.
Frequently Asked Questions
As of early 2026, Cagrilintide is in Phase 3 clinical trials and is not yet approved by any major regulatory agency. It is not officially available in the UAE. CagriSema (the combination with semaglutide) is expected to seek regulatory approval in the coming years.
In Phase 2 trials, significant weight loss was observed over 26-68 weeks. The CagriSema combination showed up to 15-25% body weight reduction in trials. Appetite changes would be expected within the first few weeks at therapeutic doses.
Cagrilintide targets amylin receptors while Semaglutide targets GLP-1 receptors — completely different hormonal pathways. This is why the combination (CagriSema) is so promising: it provides dual-mechanism appetite suppression and metabolic improvement that exceeds what either pathway can achieve alone.
CagriSema is a fixed-dose combination of cagrilintide and semaglutide in a single weekly injection, developed by Novo Nordisk. It targets both amylin and GLP-1 pathways simultaneously. Phase 3 trial results show it may become the most effective medical weight loss treatment available.
Related Treatments
Medical Disclaimer: The information on this page is for educational purposes only and is not intended as medical advice. Kamura Scores reflect a combination of research evidence, safety, accessibility, and value — they are not clinical recommendations. Research citations are provided for reference; always consult the original publications for complete study details. Consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Individual results may vary.